10 results
Pilot for determining the feasibility and image quality of high resolution Tc99m-SestaMIBI imaging of lumpectomy specimens for detection, localization, and quantification of resection margins.
To analyze the difference in fT>MIC at the target site and infection rate for a single dose of 1 and 2g of cefazolin.
This trial will determine the relative incidence of CV outcomes compared to placebo forthe TZD class as a whole, rosiglitazone (RSG), and pioglitazone (PIO) when added to thetherapeutic regimen of a person with type 2 diabetes who has additional…
The primary objective is to study the effect of a 16-week treatment with a PPAR-* agonist versus placebo on effectiveness of subsequent standard treatment with PEG-IFN and RBV, measured as SVR, in previously non-responders or relapsers with CHC…
Objective: 1) to assess whether adequate serum and interstitial fluid levels of cefazolin are reached during surgery in obese and non-obese patients, 2) to develop a population pharmacokinetic model for cefazolin which allows the characterization of…
The primary objective of this study is to evaluate the effects of SYR-322 and SYR-322coadministered with pioglitazone HC1 versus placebo on postprandial triglycerides in subjectswith type 2 diabetes.
The objective of the study is to evaluate the efficacy of the addition of SYR-322 (25 mg) to subjects who are inadequately controlled on pioglitazone HCl (30 mg) and metformin (*1500 mg or MTD).
The aim of this multicenter open-label, randomized controlled trial is to investigate the superiority of 5 days (extended) versus a single dose of cefazolin prophylaxis in revision arthroplasty of the hip and knee.
To determine whether 4 weeks of total antibiotic treatment duration is non-inferior to 6 weeks in patients with complicated SAB who have responded well to the initial treatment.
The primary objective is to determine the penetration of cefazolin and clindamycin in synovial fluid and bone tissue related to the serum concentration in subjects undergoing reimplantation of the hip.